We are delighted to share the news: MB Therapeutics secures funding through the Créalia fund. This funding accelerates the innovation driven by the MB Therapeutics team.

With the strong support of Créalia, MB Therapeutics is fully committed to the advancement of its innovative solution. This solution will enable the automated production of personalized medicines using pharmaceutical 3D printing technology. This step reinforces MB Therapeutics' position as a pioneer in the sector, determined to revolutionize the way medicines are manufactured.